Neurotech International Ltd (nti) Logo

Neurotech International Ltd (NTI)

___:___ · Healthcare

NTI Chart


NTI's Principal Activity is the conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of its proprietary cannabis strains. commercialising Mente, the world first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) +8.29%
vs ASX 200 (1yr) +4.19%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,412 of 2,411
Sector Rank 122 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies LDX / ATH / AGH
EPS -$0.011
DPS $0.00
Book Value Per Share $0.01

Broker Consensus

NTI is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Neurotech International Limited (NTI) is a medical device and solutions company whose primary mission is to improve the lives of people with neurological conditions. NTI operates in one segment being Medical Device Development and Distribution. The Company incorporated in Australia, operating through its wholly-Owned, malta-based subsidiary, AAT Research Limited.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Nedlands WA 6009
Registry Automic Group
Auditor BDO Audit (WA) Pty Ltd
Date Listed 4 Nov 2016

Upcoming Calendar (Forecasted)

Date Event
29/07/2022 Report (Quarterly)
29/08/2022 Report (Prelim)
29/08/2022 Report (Annual)
18/10/2022 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Alexandra Andrews Chief Executive Officer Mar 2022
Professor Allan Cripps Non-Executive Director May 2021

Professor Allan Cripps

Non-Executive Director

Prof Cripps is currently a Prof Emeritus in the School of Medicine and Dentistry and the Menzies Health Institute Queensland at Griffith University, Australia. He is a member of the Infection and Immunity Research Team at the Menzies Health Institute Queensland at Griffith University, Australia. He is recognised nationally and internationally as a distinguished academic, clinical scientist and health services leader and has made significant contributions in immunology, vaccine development, diagnostics health services delivery and professional health education. The focus of Prof Cripps' research activities over the last 5 decades have been in the field of immunology and inflammation. In 2015 he was awarded an Officer of the Order of Australia (AO) in recognition of his contributions to mucosal immunization, public health and higher education. Prof Cripps has experience in the development of immunity in children and mucosal immune mechanisms, in recent years he has made a significant contribution to the field of immunology through translational research and human clinical studies. Prof Cripps is also a co-inventor on several patents in the fields of diagnostic technology and vaccine protein antigens for respiratory infection. He has published over 325 peer reviewed scientific papers and presented at many national and international scientific conferences.

Ms Krista Bates Non-Executive Director Apr 2021

Ms Krista Bates

Non-Executive Director

Ms Bates is an experienced non-executive and executive director of listed companies (Australian Stock Exchange and London Stock Exchange) and various private companies in multiple jurisdictions. She is commercially experienced, particularly talented in turnarounds, structuring, risk mitigation and strategic roll-out of commercial initiatives. She has an exceptional legal background with over 23 years' experience in the legal market, with experience working in emerging markets in both a commercial and legal capacity. Ms Bates is currently a Non-executive Director of AusCann Holdings (ASX:AC8), Australian Cannabis Ventures and Australia-Africa Minerals & Energy Group. She was also a Corporate Partner at Lavan law firm, where she is Head of Mining & Resources Group and Head of Medical Cannabis Group. She is the founder of KB Corporate Advisors which provides legal and corporate advisory services.

Mr Brian Willoughby Leedman Non-Executive Chairman,Non-Executive Director Oct 2020

Mr Brian Willoughby Leedman

Non-Executive Chairman,Non-Executive Director

Mr Leedman is formerly the Chairman (WA) of Ausbiotech, Founder and Executive Director of ResApp Health, Founder of Oncosil Medical and Biolife Sciences Limited (acquired by Imugene Limited) and Non-executive Director of Alcidion Corporation and former Chairman of NeuroScientific Biopharmaceuticals. He is presently the Chairman of NeuroScientific Biopharmaceuticals and Chairman of Nutritional Growth Solutions. He has over 15 years' experience in the biotechnology sector.

Mr Winton William Willesee Non-Executive Director Apr 2019

Mr Winton William Willesee

Non-Executive Director

Mr Willesee is an experienced company director and secretary with over 20 years' experience in various roles within the Australian capital markets. Mr Willesee has experience with ASX listed and other companies over a range of industries having been involved with many successful ventures from early stage through to large capital development projects. He has a core expertise in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance

Mr Mark Davies Non-Executive Director Apr 2019

Mr Mark Davies

Non-Executive Director

Mr Davies has over 20 years' experience in trading, investment banking and providing corporate advice. He worked at Montagu Stockbrokers before co-founding investment banking firm Cygnet Capital and more recently 1861 Capital. Mark specialises in providing corporate advice and capital raising services to emerging companies seeking business development opportunities and funding from the Australian market.

Ms Erlyn Dale Company Secretary Apr 2019
Alexandra Andrews Chief Executive Officer N/A

Director Transactions

NTI directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
13/12/21 Allan Cripps Issued 500,000 $0.058 $29,000 Issue of options
13/12/21 Krista Bates Issued 500,000 $0.058 $29,000 Issue of options
01/11/21 Krista Bates Transfer 450,000 $0.061 $27,450 Off-market transfer
01/11/21 Krista Bates Transfer 450,000 $0.061 $27,450 Off-market transfer
14/07/21 Allan Cripps Buy +180,000 $0.056 $10,017 On-market trade
14/07/21 Krista Bates Buy +180,000 $0.056 $10,044 On-market trade
22/06/21 Brian Leedman Buy +933,589 $0.054 $49,961 On-market trade
13/04/21 Krista Bates Buy +270,000 $0.074 $19,980 On-market trade
22/12/20 Brian Leedman Issued 2,272,727 $0.022 $49,999 Placement
17/12/20 Winton Willesee Issued 2,000,000 $0.056 $112,000 Issue of options
17/12/20 Mark Davies Issued 2,000,000 $0.056 $112,000 Issue of options
17/12/20 Brian Leedman Issued 20,000,000 $0.056 $1,120,000 Issue of options
05/10/20 Winton Willesee Transfer 1,252,852 $0.013 $16,287 Off-market transfer
05/10/20 Winton Willesee Issued 6,047,382 $0.008 $48,500 Director remuneration
30/09/20 Peter Griffiths Issued 16,957,606 $0.008 $136,000 Director remuneration
30/09/20 David Cantor Issued 4,551,122 $0.008 $36,499 Director remuneration
30/09/20 Mark Davies Issued 7,793,017 $0.008 $62,499 Director remuneration
18/11/19 David Cantor Buy +2,000,000 $0.014 $28,000 As advised by the company
18/11/19 Mark Davies Buy +2,000,000 $0.014 $28,000 As advised by the company
18/11/19 Winton Willesee Buy +2,000,000 $0.014 $28,000 As advised by the company
18/11/19 Peter Griffiths Buy +11,929,754 $0.014 $167,017 As advised by the company

Director Interests

The current holdings of NTI directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Krista Bates 13/12/2021 0 450,000 500,000 N/A
Allan Cripps 13/12/2021 180,000 N/A 500,000 N/A
Mark Davies 30/06/2021 N/A 7,793,017 4,000,000 N/A
Brian Leedman 30/06/2021 2,272,727 933,589 20,000,000 N/A
Winton Willesee 30/06/2021 N/A 5,132,436 4,000,000 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Aug 1, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Quadrangle Capital Pty Ltd 44,000,000 6.31%
Citicorp Nominees Pty Limited 34,487,677 4.95%
Jalaver Pty Ltd <Falcon Pension A/C> 33,900,000 4.87%
J & J Bandy Nominees Pty Ltd <Bandy P/F A/C> 33,500,000 4.81%
Gleneagle Securities Nominees Pty Limited 32,860,371 4.72%
The Trust Company (Australia) Limited <Mof A/C> 25,250,245 3.62%
Greywood Holdings Pty Ltd 22,800,000 3.27%
Dolce Cann Global Pty Ltd 22,000,000 3.16%
Spinite Pty Ltd 17,954,426 2.58%
Mrs Melanie Therese Verheggen 15,818,956 2.27%
Chincherinchee Nominees Pty Ltd 12,596,786 1.81%
Mr Stephen John Dobson 11,096,786 1.59%
Chincherinchee Nominees Pty Ltd I 10,096,786 1.45%
TIGA Trading Pty Ltd 7,812,500 1.12%
Haslingden Pty Ltd <Grids S/F A/C> 7,800,000 1.12%
Seivad Investments Pty Ltd 7,793,017 1.12%
Ms Chunyan Niu 7,330,000 1.05%
Dynamic Supplies Investments Pty Ltd 7,244,292 1.04%
BR Corporation Pty Ltd 7,050,000 1.01%
The Sun W Investment Pty Ltd <Sun Family A/C> 6,727,272 0.97%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 45 113 239 806 431 1,634

Substantial Shareholders

No Substantial Shareholders for NTI in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.052 30 June
2020 $0.008 30 June
2019 $0.018 28 June
2018 $0.16 29 June
2017 $0.25 28 June
NTI Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.